Grabar Law Office Investigates Fiduciary Breach Claims Against ADMA Biologics, Commvault Systems, Erasca, and Hub Group

GlobeNewswire··Read original
2▲0 ▼4Impact / 5
Summary · why it matters

Grabar Law Office is investigating potential fiduciary duty breaches by officers and directors of ADMA Biologics, Commvault Systems, Erasca, and Hub Group. For ADMA Biologics, the probe concerns allegations of inadequate internal controls, channel-stuffing, and undisclosed related-party transactions, with a March 2026 research report claiming revenue growth was overstated. The Commvault investigation focuses on allegedly misleading statements about annual recurring revenue growth guidance for fiscal year 2026. Erasca is under scrutiny for allegedly making improper comparisons between its drug candidate ERAS-0015 and Revolution Medicines' RMC-6236, and for failing to disclose related intellectual property risks, with the stock declining after April 2026 disclosures of a patient death and patent infringement allegations. Hub Group is alleged to have issued financial statements from Q1 2023 to Q3 2025 containing material misstatements due to premature revenue recognition and understated transportation costs. Long-term shareholders who purchased before specified dates and still hold shares may seek corporate reforms and damages at no cost.

Impact on assets 4

Biotech & Genomic Medicine▼ · 2 stocks
ADMA Biologics Inc
ADMA
▼ NegativeRegulationrelevance

Investigation into fiduciary breaches, inadequate internal controls, channel-stuffing, and undisclosed related-party transactions.

Erasca Inc
ERAS
▼ NegativeRegulationrelevance

Investigation into improper comparisons, undisclosed IP risks, patient death, and patent infringement allegations.

Cybersecurity & Digital Trust▼ · 1 stocks
CommVault Systems Inc
CVLT
▼ NegativeRegulationrelevance

Investigation into allegedly misleading statements about annual recurring revenue growth guidance for fiscal year 2026.

Industrials▼ · 1 stocks
Hub Group Inc
HUBG
▼ NegativeRegulationrelevance

Investigation into material misstatements due to premature revenue recognition and understated transportation costs.

© 2026 MarketIVNews